Viewing Study NCT07052305

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:37 AM
Ignite Modification Date: 2026-07-22 @ 2:58 PM
Study NCT ID: NCT07052305
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-12-08
First Post: 2025-06-26
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Yescarta® (Axicabtagene Ciloleucel) or Post-Breyanzi® (Lisocabtagene Maraleucel) in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Sponsor: Washington University School of Medicine
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Large B-cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non-Hodgkins Lymphoma View
None Large B-cell Lymphoma View
None Yescarta View
None Axi-cel View
None Breyanzi View
None Liso-cel View
None Interleukin 7 View
None NT-I7 View
None CD19 CAR T-cell Therapy View